688331 荣昌生物
交易中 02-24 13:55:07
资讯
新帖
简况
2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股
证券之星 · 02-10
2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股
花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元
智通财经 · 02-05
花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间
金吾财讯 · 02-03
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
智通财经 · 02-02
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
证券之星 · 02-01
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
南方财经网 · 01-30
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
3万亿赛道的估值锚点，彻底变了
虎嗅APP · 01-26
3万亿赛道的估值锚点，彻底变了
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
证券之星 · 01-25
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
智通财经 · 01-23
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
智通财经 · 01-23
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
老虎资讯综合 · 01-23
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
证券之星 · 01-21
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
荣昌生物：首次回购19.4144万股
南方财经网 · 01-20
荣昌生物：首次回购19.4144万股
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
金吾财讯 · 01-19
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
证券之星 · 01-18
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
每日经济新闻 · 01-16
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
金吾财讯 · 01-16
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
智通财经 · 01-16
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
荣昌生物：调整回购股份价格上限至116元/股
每日经济新闻 · 01-15
荣昌生物：调整回购股份价格上限至116元/股
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":98.04,"timestamp":1771912507000,"preClose":101.19,"halted":0,"volume":4740462,"delay":0,"changeRate":-0.0311,"floatShares":163000000,"shares":564000000,"eps":-1.6788,"marketStatus":"交易中","change":-3.15,"latestTime":"02-24 13:55:07","open":102.6,"high":103,"low":97,"amount":467000000,"amplitude":0.0593,"askPrice":98.05,"askSize":3,"bidPrice":98.04,"bidSize":1,"shortable":0,"etf":0,"ttmEps":-1.6788,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1771916400000},"marketStatusCode":2,"adr":0,"adjPreClose":101.19,"symbolType":"stock_kcb","openAndCloseTimeList":[[1771896600000,1771903800000],[1771909200000,1771916400000]],"highLimit":111.31,"lowLimit":91.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":24.62,"roa":"--","roe":"--","epsLYR":-2.73,"committee":0.364929,"marketValue":55341000000,"turnoverRate":0.0291,"status":1,"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":77.5,"timestamp":1771912496571,"preClose":82.05,"halted":0,"volume":2246120,"delay":0,"premium":"-30.36"},"floatMarketCap":15990000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2610120676","title":"2月10日荣昌生物涨5.23%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610120676","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610120676?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:33","pubTimestamp":1770712383,"startTime":"0","endTime":"0","summary":"证券之星消息，2月10日荣昌生物涨5.23%，收盘报106.71元，换手率4.14%，成交量6.75万手，成交额7.15亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家；过去90天内机构目标均价为151.81。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000026067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1574","BK0239","LU1969619763.USD","160916","LU1064131003.USD","BK1161","LU1064130708.USD","LU2148510915.USD","09995","LU2328871848.SGD","LU2488822045.USD","688331"],"gpt_icon":0},{"id":"2609208843","title":"花旗：重新予荣昌生物“买入/高风险”评级 目标价105港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609208843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609208843?lang=zh_cn&edition=full","pubTime":"2026-02-05 17:17","pubTimestamp":1770283020,"startTime":"0","endTime":"0","summary":"花旗发布研报称，在暂停评级一段时间后，重新给予荣昌生物(09995)“买入/高风险”评级，目标价为105港元。因集团与艾伯维就PD-1/VEGF双特异性药物RC148达成合作，进一步拓展其管线候选药物 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260205/c674581585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"gpt_icon":0},{"id":"2608849407","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好2026年主业利润率进一步改善的空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2608849407","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608849407?lang=zh_cn&edition=full","pubTime":"2026-02-03 13:29","pubTimestamp":1770096543,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，荣昌生物 发布2025年年度业绩预告，预计全年营业收入约32.5亿元，同比增长约89%；净利润约7.16 亿元，扣非净利润约7,850万元，均同比扭亏为盈。据公告，业绩高增长主因核心产品国内市场商业化持续放量、BD收入确认显著增厚利润端、运营效率持续优化。随着泰它西普和RC148出海后、更多研发费用由海外合作伙伴承担，该机构看好2026年主业利润率进一步改善的空间。该机构维持公司136港元的目标价，维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1974464","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2608384558","title":"港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2608384558","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608384558?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:25","pubTimestamp":1769995522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盈喜后涨近4%，截至发稿，涨3.68%，报87.3港元，成交606.74万港元。消息面上，1月30日，荣昌生物发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","688331","VT"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1328615791.USD","BK4017","BK0077","BK0188","LU1064130708.USD","688506","09995","LU1223083913.SGD","BK1583","LU2580892789.USD","LU1223082519.USD","BK0239","LU1969619763.USD","BK0046","BK0028","LU2328871848.SGD","LU2488822045.USD","BK0057","LU2580892862.HKD","BK0196","LU1064131003.USD","BK1161","LU1223082196.USD","688331","BK1574","300122","LU2148510915.USD","000661","CDE","BK0075"],"gpt_icon":0},{"id":"2608072430","title":"每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072430","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072430?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:32","pubTimestamp":1769880732,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，荣昌生物报收于102.25元，较上周的102.27元下跌0.02%。本周，荣昌生物1月30日盘中最高价报107.5元。业绩披露要点荣昌生物发布业绩预告，预计2025年全年归属净利润盈利约7.16亿元。公司公告汇总荣昌生物预计2025年度营业收入约325,000万元，同比增长约89%；归属于母公司所有者的净利润约71,600万元，实现扭亏为盈；扣除非经常性损益后的净利润约7,850万元，亦实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK1574","LU2148510915.USD","BK1583","09995","688331","LU1064130708.USD","LU2328871848.SGD","LU2488822045.USD","LU1969619763.USD","BK1161","BK0239"],"gpt_icon":0},{"id":"2607401314","title":"荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607401314","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607401314?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:25","pubTimestamp":1769765136,"startTime":"0","endTime":"0","summary":"南财智讯1月30日电，荣昌生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约为71,600万元，实现扭亏为盈；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润约为7,850万元，实现扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637048943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","09995"],"gpt_icon":0},{"id":"2606122293","title":"3万亿赛道的估值锚点，彻底变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122293","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606122293?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:12","pubTimestamp":1769386320,"startTime":"0","endTime":"0","summary":"多只创新药ETF的年内最高涨幅突破50%，多家创新药企股价翻番。不过，我们发现经过验证的靶点，不同企业的BD交易授权下，资本市场也给出了不同反应。且2024年，美国FDA批准了同类首款药物Ensifentrine，为该靶点的成药性提供了关键验证。只不过与海思科不同，恒瑞医药在与GSK的交易公告后，其A股和H股股价均出现了显著上涨。据悉，恒瑞医药获得的5亿美元为纯现金首付款，可以立即确认业绩，展现了GSK对其资产价值的强烈认可和信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656147805&idx=1&sn=bc6bcda7f82ce0193ae3a090ba46cdc8&chksm=67838d5482c3a023e3be79b5567544c3a508a60a147222d217af39c881d77ba875ce4eab9a04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","BK0239","GSK","GSK.UK","BK4007","LU2488822045.USD","LU1064131003.USD","LU2148510915.USD","LU1829250122.USD","LU1969619763.USD","LU1064130708.USD","LU2328871848.SGD","BK4153","BK1574","BK1583","BK1161","BK4532","688331","09995","BK4585","AA","BK4588"],"gpt_icon":0},{"id":"2606234089","title":"每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234089","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234089?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:04","pubTimestamp":1769277852,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，荣昌生物报收于102.27元，较上周的107.25元下跌4.64%。本周，荣昌生物1月19日盘中最高价报109.38元。本周关注点公司公告汇总：荣昌生物首次回购股份19.4144万股，支付资金总额2000.40万元。荣昌生物制药（烟台）股份有限公司完成2022年及2023年A股限制性股票激励计划相关权益归属，共计归属767,240股，涉及激励对象142人。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","LU1064131003.USD","LU1969619763.USD","LU2488822045.USD","BK1583","LU2148510915.USD","BK1161","688331","09995","LU2328871848.SGD","LU1064130708.USD"],"gpt_icon":0},{"id":"2605262484","title":"瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605262484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605262484?lang=zh_cn&edition=full","pubTime":"2026-01-23 13:58","pubTimestamp":1769147880,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，将荣昌生物(09995)的评级由“中性”上调至“买入”，目标价由63.8港元一举升至120港元。瑞银对荣昌生物与艾伯维集团(AbbVie)的合作持积极看法，该合作授予RC148(PD-1/VEGF) ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260123/c674256316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"gpt_icon":0},{"id":"2605744726","title":"港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2605744726","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605744726?lang=zh_cn&edition=full","pubTime":"2026-01-23 10:41","pubTimestamp":1769136116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨近4%，截至发稿，涨2.96%，报92.3港元，成交2.06亿港元。该行认为，艾伯维作为一间跨国制药公司，应能促进RC148在研发和商业化方面的全球扩展，并对RC148的差异化发展策略持正面态度。该行相信，首付款支付将扭转荣昌生物的净负债状况，并预计未来多项新药获批将使公司自2026年起持续达到盈亏平衡。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1610","BK1574","BK0239","LU1969619763.USD","LU1064131003.USD","BK1161","LU1064130708.USD","LU2148510915.USD","09995","LU2328871848.SGD","LU2488822045.USD","688331"],"gpt_icon":0},{"id":"1199361007","title":"港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199361007","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199361007?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133269,"startTime":"0","endTime":"0","summary":"1月23日，港股生物医药股普涨，$康方生物(09926)$涨超5%，$荣昌生物(09995)$涨超3%，$泰格医药(03347)$、$君实生物(01877)$、$百济神州(06160)$、$药明合联(02268)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de741e781d04bd03f8ca00d2fa57ffc6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU0348766576.USD","BK1574","LU1961090484.USD","LU2328871848.SGD","BK1161","LU0634319403.HKD","09995","02800","LU1720050803.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU2476274308.USD","688331","LU0417516738.SGD","BK0239","09926","LU2399975544.HKD","LU0561508036.HKD","399441","BK4585","LU2148510915.USD","LABU","LU0417516571.SGD","LU2476274720.SGD","LU1794554557.SGD","LU0348784397.USD","BK1610","LU2488822045.USD","LU1064130708.USD","BK1583","LU0348767384.USD","LU1064131003.USD","LU1969619763.USD","BK4588","LU0348827113.USD","LU0417516902.SGD","LU0348783233.USD","LU2778985437.USD","LU0348825331.USD","161726","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2605488754","title":"荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605488754?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:17","pubTimestamp":1769005037,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，荣昌生物报收于103.53元，较前一交易日下跌0.07%，最新总市值为584.4亿元。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司已完成2022年及2023年A股限制性股票激励计划相关权益的归属，共计归属767,240股，涉及激励对象142人。本次归属新增股份已于2026年1月20日完成登记，上市流通日期为2026年1月26日。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","LU1969619763.USD","BK1583","688331","BK0239","LU2488822045.USD","BK1574","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2604923661","title":"荣昌生物：首次回购19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923661","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923661?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:53","pubTimestamp":1768906388,"startTime":"0","endTime":"0","summary":"南财智讯1月20日电，荣昌生物公告，公司于2026年1月20日通过上海证券交易所交易系统以集中竞价交易方式首次回购股份194,144股，占公司总股本的0.0344%，回购价格区间为102.17元/股至103.78元/股，支付资金总额为2000.40万元（不含交易费用）。本次回购方案已实施完成，实际回购金额为2000.40万元，在预计回购金额2000万元至4000万元范围内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624836419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","688331","LU1064131003.USD","LU2488822045.USD","BK1161","LU1064130708.USD","LU1969619763.USD","LU2148510915.USD","LU2328871848.SGD","BK1574","BK0239"],"gpt_icon":0},{"id":"2604864900","title":"【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2604864900","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604864900?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:47","pubTimestamp":1768801676,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，荣昌生物 日前与全球行业巨头艾伯维签订关于肿瘤领域的双抗药物RC148的授权协议，公司将授予艾伯维RC148在大中华区以外地区的的开发、生产和商业化的独家权利，协议获准后公司将获6.5亿美元的首付款及最高49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华以外地区净销售额的两位数分级特许权使用费。艾伯维的认可表明产品临床数据优异，而且首付款将显著夯实资金。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2604928774","title":"每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928774","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928774?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:59","pubTimestamp":1768672747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，荣昌生物报收于107.25元，较上周的96.96元上涨10.61%。本周，荣昌生物1月13日盘中最高价报114.46元。本周关注点交易信息汇总：荣昌生物因涨幅达15%登上龙虎榜。公司公告汇总：荣昌生物与艾伯维签署RC148全球授权协议，获6.5亿美元首付款及最高49.5亿美元里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0239","BK1583","LU1969619763.USD","LU2148510915.USD","BK1161","LU1064130708.USD","LU2328871848.SGD","09995","BK1574","LU2488822045.USD","688331"],"gpt_icon":0},{"id":"2603967864","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967864","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603967864?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:25","pubTimestamp":1768559151,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问近两年是否出口欧盟国家？荣昌生物（688331.SH）1月16日在投资者互动平台表示，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622035255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622035255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","BK1574","LU1064130708.USD","BK1583","LU1064131003.USD","LU2148510915.USD","BK1161","LU2328871848.SGD","LU2488822045.USD","09995","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2603954004","title":"荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954004","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954004?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:35","pubTimestamp":1768541754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)股价午后维持高位，截至发稿，升3.45%，报97.65港元，成交额3.21亿港元。交银国际研究报告指，荣昌生物与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，荣昌生物将收到6.5亿美元首付，并最高49.5亿美元的里程碑收款，以及两位数百分比的分级销售提成。该行上调荣昌生物2026至27年的收入预测，升目标价至136港元。2026年看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的进展。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","BK1161","09995","BK1574","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","BK1583","LU1064130708.USD","LU2148510915.USD","LU1969619763.USD","BK0239"],"gpt_icon":0},{"id":"2603349619","title":"智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603349619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603349619?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:52","pubTimestamp":1768521142,"startTime":"0","endTime":"0","summary":"修订后的eCTD相关技术文件由国家药监局药品审评中心另行发布。国家电网“十五五”计划投资4万亿元据中国电力报消息，国家电网“十五五”投资计划出炉：“十五五”期间，国家电网公司固定资产投资预计达到4万亿元，较“十四五”投资增长40%;将重点聚焦于绿色转型、构建新型电力系统、强化科技赋能等方面。持有屈臣氏集团25%股份的淡马锡寻求在其IPO中退出投资。双方所持股份均设有5年锁定期。2025年公司获得钠电千吨级订单并出货。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a50ec980ff2cb7251ac80144af961f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK1592","ZNmain","LU1481107354.HKD","BK4505","BK1587","UBmain","LU0072462343.USD","BK4526","BK4534","02579","300919","BK1151","CKHUY","ZBmain","NIO","03993","09995","BK4099","BK4509","BK1583","EVS.SI","TNmain","BK1521","LU0052750758.USD","LU1880383366.USD","BK4532","LU1969619763.USD","02190","BK4588","BK1116","LU1880383440.USD","002352","BK1110","LU1571399168.USD","BK1569","LU0164880469.USD","LU2328871848.SGD","LU2213484517.USD","BK1601","LU0708995583.HKD","ZTmain","00001","09866","BK1230","BK4585","BK1161","BK4548","603906","BK1500","LU0320764599.SGD","BK1594","BK4504","688331","06936","BK4555","603993","BK1574","BK1100","LU0149721374.USD","BK4574","BK4581","NIO.SI","BK1190","ZFmain","LU1048588211.SGD","IE0032431581.USD","02465"],"gpt_icon":1},{"id":"2603670626","title":"荣昌生物：调整回购股份价格上限至116元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603670626","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603670626?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:55","pubTimestamp":1768467316,"startTime":"0","endTime":"0","summary":"【荣昌生物：调整回购股份价格上限至116元/股】1月15日，荣昌生物公告称，公司拟将回购价格上限由95元/股调整为116元/股，以保障回购股份方案顺利实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620451798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620451798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1064130708.USD","LU2488822045.USD","688331","BK1574","BK1583","LU2148510915.USD","09995","LU2328871848.SGD","LU1969619763.USD","LU1064131003.USD","BK1161"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1771912511041,"stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":-0.0208},{"period":"3month","weight":0.1233},{"period":"6month","weight":0.3143},{"period":"1year","weight":2.4785},{"period":"ytd","weight":0.3008}],"compareEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":-0.0107},{"period":"3month","weight":0.0229},{"period":"6month","weight":0.1042},{"period":"1year","weight":0.2249},{"period":"ytd","weight":0.0285}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10696股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}